Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

• Published in: Arthritis research & therapy Vol. 23; no. 1; pp. 1 - 228
• Main Authors: Hirose, Wataru, Harigai, Masayoshi, Amano, Koichi, Hidaka, Toshihiko, Itoh, Kenji, Aoki, Kazutoshi, Nakashima, Masahiro, Nagasawa, Hayato, Komano, Yukiko, Nanki, Toshihiro, Akiyama, Yuji, Ando, Souichirou, Hashiba, Yayoi, Kaneko, Motohide, Kawagoe, Mitsuhiro, Kondo, Tsuneo, Kubo, Kazuyoshi, Masuda, Ikuko, Matsumoto, Mitsuyo, Okada, Yusuke, Shibata, Akiko, Suzuki, Kimihiro, Takamatsu, Ko, Takei, Hirofumi
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 31.08.2021; BioMed Central; BMC
• Subjects: Abatacept; Antigenic determinants; Arthritis; Bias; Clinical outcomes; Dosage and administration; Drug therapy; Drugs; Enrollments; Genetic aspects; Health aspects; Histocompatibility antigens; HLA histocompatibility antigens; Patient outcomes; Patients; Physiological aspects; Propensity score matching; Remission (Medicine); Retention; Rheumatoid arthritis; Rheumatology; Shared epitope; Tofacitinib; Japan

Abstract Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). Methods After adjustments by propensity score match...